Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.

Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD.

Calcif Tissue Int. 2020 Apr;106(4):386-391. doi: 10.1007/s00223-019-00653-7. Epub 2020 Jan 2.

PMID:
31897528
2.

Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD.

J Bone Miner Res. 2020 Jan;35(1):20-27. doi: 10.1002/jbmr.3860. Epub 2019 Oct 11.

PMID:
31603996
3.

Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.

Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid IR, Gamble GD, Grey A.

Calcif Tissue Int. 2019 Oct;105(4):423-429. doi: 10.1007/s00223-019-00579-0. Epub 2019 Jun 27.

PMID:
31250043
4.

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17. No abstract available.

PMID:
31087124
5.

Fracture Prevention with Zoledronate in Older Women with Osteopenia. Reply.

Reid IR, Horne AM, Gamble GD.

N Engl J Med. 2019 Mar 28;380(13):1288. doi: 10.1056/NEJMc1900923. No abstract available.

PMID:
30917270
6.

Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women.

Bristow SM, Horne AM, Gamble GD, Mihov B, Stewart A, Reid IR.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3576-3584. doi: 10.1210/jc.2019-00111.

PMID:
30896743
7.

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

J Intern Med. 2019 Aug;286(2):221-229. doi: 10.1111/joim.12901. Epub 2019 Apr 8.

PMID:
30887607
8.

Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.

Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid I, Gamble GD, Grey A.

J Bone Miner Res. 2019 Jul;34(7):1248-1253. doi: 10.1002/jbmr.3712. Epub 2019 May 29.

PMID:
30870576
9.
10.

Fracture Prevention with Zoledronate in Older Women with Osteopenia.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1.

PMID:
30575489
11.

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14.

PMID:
29445836
12.

Longitudinal Examination of Aggression and Study Skills From Middle to High School: Implications for Dropout Prevention.

Orpinas P, Raczynski K, Hsieh HL, Nahapetyan L, Horne AM.

J Sch Health. 2018 Mar;88(3):246-252. doi: 10.1111/josh.12602.

PMID:
29399843
13.

Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M, Taylor L, Fenwick S, Camargo CA, Stewart AW, Scragg R.

J Intern Med. 2017 Nov;282(5):452-460. doi: 10.1111/joim.12651. Epub 2017 Jul 26.

14.

Dietary calcium intake and rate of bone loss in men.

Bristow SM, Gamble GD, Horne AM, Reid IR.

Br J Nutr. 2017 May;117(10):1432-1438. doi: 10.1017/S0007114517001301. Epub 2017 Jun 13.

PMID:
28606219
15.

Bone Loss After Denosumab: Only Partial Protection with Zoledronate.

Reid IR, Horne AM, Mihov B, Gamble GD.

Calcif Tissue Int. 2017 Oct;101(4):371-374. doi: 10.1007/s00223-017-0288-x. Epub 2017 May 13.

PMID:
28500448
16.

Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry.

Kalluru R, Petrie KJ, Grey A, Nisa Z, Horne AM, Gamble GD, Bolland MJ.

BMJ Open. 2017 Feb 10;7(2):e013703. doi: 10.1136/bmjopen-2016-013703.

17.

Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women.

Billington EO, Bristow SM, Gamble GD, de Kwant JA, Stewart A, Mihov BV, Horne AM, Reid IR.

Osteoporos Int. 2017 Jan;28(1):119-125. doi: 10.1007/s00198-016-3744-y. Epub 2016 Aug 20.

PMID:
27543500
18.

Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial.

Bristow SM, Gamble GD, Pasch A, O'Neill WC, Stewart A, Horne AM, Reid IR.

Osteoporos Int. 2016 Mar;27(3):1209-1216. doi: 10.1007/s00198-015-3372-y. Epub 2015 Oct 22.

PMID:
26493812
19.

Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women.

Bristow SM, Gamble GD, Stewart A, Horne AM, Reid IR.

Br J Nutr. 2015 Dec 14;114(11):1868-74. doi: 10.1017/S0007114515003694. Epub 2015 Sep 30.

PMID:
26420590
20.

Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial.

Bristow SM, Gamble GD, Stewart A, Kalluru R, Horne AM, Reid IR.

Br J Nutr. 2015 May 28;113(10):1585-94. doi: 10.1017/S000711451500080X. Epub 2015 Apr 8.

PMID:
25851635
21.

Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women.

Bristow SM, Gamble GD, Stewart A, Horne L, House ME, Aati O, Mihov B, Horne AM, Reid IR.

Br J Nutr. 2014 Nov 28;112(10):1611-20. doi: 10.1017/S0007114514002785. Epub 2014 Oct 2.

PMID:
25274192
22.

Bone density is normal and does not change over 2 years in sarcoidosis.

Bolland MJ, Wilsher ML, Grey A, Horne AM, Fenwick S, Gamble GD, Reid IR.

Osteoporos Int. 2015 Feb;26(2):611-6. doi: 10.1007/s00198-014-2870-7. Epub 2014 Aug 30.

PMID:
25172384
23.

Randomised controlled trial of vitamin D supplementation in sarcoidosis.

Bolland MJ, Wilsher ML, Grey A, Horne AM, Fenwick S, Gamble GD, Reid IR.

BMJ Open. 2013 Oct 23;3(10):e003562. doi: 10.1136/bmjopen-2013-003562.

24.

Testosterone levels following decreases in serum osteocalcin.

Bolland MJ, Grey A, Horne AM, Reid IR.

Calcif Tissue Int. 2013 Aug;93(2):133-6. doi: 10.1007/s00223-013-9730-x. Epub 2013 Apr 19.

PMID:
23604689
25.

The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.

Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, Gamble GD, Reid IR.

Osteoporos Int. 2013 Jan;24(1):349-54. doi: 10.1007/s00198-012-2117-4. Epub 2012 Aug 15.

PMID:
22893357
26.

Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.

J Clin Endocrinol Metab. 2012 Jun;97(6):1922-8. doi: 10.1210/jc.2012-1424. Epub 2012 Mar 14.

PMID:
22419728
27.

Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).

Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.

Clin Endocrinol (Oxf). 2012 May;76(5):643-8. doi: 10.1111/j.1365-2265.2011.04274.x.

PMID:
22040002
28.

Prevalent dietary supplement use in older New Zealand men.

Bacon CJ, Bolland MJ, Ames RW, Siu AT, Mason BH, Horne AM, Grey A, Reid IR.

N Z Med J. 2011 Jun 24;124(1337):55-62.

PMID:
21946878
29.

Evaluation of the FRAX and Garvan fracture risk calculators in older women.

Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, Gamble GD, Reid IR.

J Bone Miner Res. 2011 Feb;26(2):420-7. doi: 10.1002/jbmr.215.

30.

Relationships between vascular calcification, calcium metabolism, bone density, and fractures.

Wang TK, Bolland MJ, van Pelt NC, Horne AM, Mason BH, Ames RW, Grey AB, Ruygrok PN, Gamble GD, Reid IR.

J Bone Miner Res. 2010 Dec;25(12):2777-85. doi: 10.1002/jbmr.183. Epub 2010 Jul 16. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

31.

Vitamin D insufficiency and health outcomes over 5 y in older women.

Bolland MJ, Bacon CJ, Horne AM, Mason BH, Ames RW, Wang TK, Grey AB, Gamble GD, Reid IR.

Am J Clin Nutr. 2010 Jan;91(1):82-9. doi: 10.3945/ajcn.2009.28424. Epub 2009 Nov 11.

PMID:
19906799
32.

Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction.

Bolland MJ, Wang TK, van Pelt NC, Horne AM, Mason BH, Ames RW, Grey AB, Ruygrok PN, Gamble GD, Reid IR.

J Bone Miner Res. 2010 Mar;25(3):505-12. doi: 10.1359/jbmr.091005.

33.

High-dose oral vitamin D3 supplementation in the elderly.

Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR.

Osteoporos Int. 2009 Aug;20(8):1407-15. doi: 10.1007/s00198-008-0814-9. Epub 2008 Dec 20.

PMID:
19101755
34.

Does degree of baldness influence vitamin D status?

Bolland MJ, Ames RW, Grey AB, Horne AM, Mason BH, Gamble GD, Reid IR.

Med J Aust. 2008 Dec 1-15;189(11-12):674-5.

PMID:
19061473
35.

Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism.

Bolland MJ, Grey AB, Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM, Gamble GD, Reid IR.

N Z Med J. 2008 Jul 4;121(1277):18-29.

PMID:
18677327
36.

Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Callon KE, Gamble GD, Reid IR.

J Bone Miner Res. 2008 Aug;23(8):1304-8. doi: 10.1359/jbmr.080312.

37.

Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report.

Bolland MJ, Grey A, Horne AM, Thomas MG.

Ann Clin Microbiol Antimicrob. 2008 Jan 28;7:3. doi: 10.1186/1476-0711-7-3.

38.

The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency.

Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR.

Am J Clin Nutr. 2007 Oct;86(4):959-64.

PMID:
17921371
39.

Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein.

Bolland MJ, Grey AB, Ames RW, Horne AM, Mason BH, Wattie DJ, Gamble GD, Bouillon R, Reid IR.

Clin Endocrinol (Oxf). 2007 Aug;67(2):259-64. Epub 2007 Jun 4.

PMID:
17547688
40.

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.

Clin Endocrinol (Oxf). 2007 Aug;67(2):270-5. Epub 2007 Jun 4.

PMID:
17547686
41.

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.

J Clin Endocrinol Metab. 2007 Apr;92(4):1283-8. Epub 2007 Jan 16.

PMID:
17227801
42.

The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women.

Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR.

Osteoporos Int. 2007 Apr;18(4):479-86. Epub 2006 Nov 21.

PMID:
17120180
43.

Determinants of vitamin D status in older men living in a subtropical climate.

Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR.

Osteoporos Int. 2006 Dec;17(12):1742-8. Epub 2006 Aug 24.

PMID:
16932872
44.

Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.

Clin Endocrinol (Oxf). 2006 Aug;65(2):191-7.

PMID:
16886959
45.

Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women.

Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR.

Bone. 2006 Mar;38(3):317-21. Epub 2005 Sep 30.

PMID:
16199216
46.

Determinants of vitamin D status in older women living in a subtropical climate.

Lucas JA, Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR.

Osteoporos Int. 2005 Dec;16(12):1641-8. Epub 2005 Jul 19.

PMID:
16027959
47.

A teacher-focused approach to prevent and reduce students' aggressive behavior: the GREAT Teacher Program.

Orpinas P, Horne AM; Multisite Violence Prevention Project.

Am J Prev Med. 2004 Jan;26(1 Suppl):29-38.

48.

Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.

Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD.

Am J Med. 2000 Oct 1;109(5):362-70.

PMID:
11020392
49.

Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women.

Orr-Walker BJ, Horne AM, Evans MC, Grey AB, Murray MA, McNeil AR, Reid IR.

J Clin Endocrinol Metab. 1999 Jun;84(6):1997-2001.

PMID:
10372700
50.

Marital satisfaction and social learning family therapy for child conduct problems: generalization of treatment effects.

Sayger TV, Horne AM, Glaser BA.

J Marital Fam Ther. 1993 Oct;19(4):393-402. doi: 10.1111/j.1752-0606.1993.tb01001.x.

PMID:
21118477

Supplemental Content

Loading ...
Support Center